Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
40.86
-0.65 (-1.57%)
At close: Oct 3, 2025, 4:00 PM EDT
41.00
+0.14 (0.34%)
After-hours: Oct 3, 2025, 7:41 PM EDT
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover Crinetics Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $74.45, which forecasts a 82.21% increase in the stock price over the next year. The lowest target is $40 and the highest is $143.
Price Target: $74.45 (+82.21%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 5 | 5 | 2 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 10 | 10 | 7 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $73 → $87 | Buy | Maintains | $73 → $87 | +112.92% | Sep 30, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $65 → $77 | Buy | Maintains | $65 → $77 | +88.45% | Sep 29, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $80 → $88 | Buy | Maintains | $80 → $88 | +115.37% | Sep 29, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $35 → $40 | Hold | Maintains | $35 → $40 | -2.10% | Sep 26, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $86 → $143 | Buy | Maintains | $86 → $143 | +249.98% | Sep 26, 2025 |
Financial Forecast
Revenue This Year
5.92M
from 1.04M
Increased by 469.59%
Revenue Next Year
47.66M
from 5.92M
Increased by 705.27%
EPS This Year
-4.85
from -3.69
EPS Next Year
-5.10
from -4.85
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 114.2M | |||
| Avg | 5.9M | 47.7M | |||
| Low | 2.7M | 24.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 910.6% | 1,830.0% | |||
| Avg | 469.6% | 705.3% | |||
| Low | 164.1% | 315.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.28 | -3.29 | |||
| Avg | -4.85 | -5.10 | |||
| Low | -5.24 | -6.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.